Arbeitsgruppe DUMITRU

Forschung Dumitru 


Glioblastoma (GBM) is one of the deadliest types of cancer. It can occur in both adults and children. Despite aggressive therapeutic approaches, 95% of GBM patients die within 5 years after diagnosis.

Our studies aim to characterize the molecular mechanisms involved in GBM pathophysiology, in particular the mechanisms controlling tumor cell proliferation, invasion and resistance to therapy. To this end, we use a multilateral experimental design consisting of in vitro molecular and functional studies, in vivo studies on murine models and in situ analysis of tissue from GBM patients.

Furthermore, we conduct prospective (NeuroCAM) and retrospective (NeuroBIOM) studies on biomaterials from GBM patients in order to identify novel Biomarkers with improved prognostic and predictive accuracy in this type of cancer.

Group Members

Principal Investigator



Cooperation Partners

  • Prof. Meliha Karsak, ZMNH, University Medical Center Hamburg-Eppendorf
  • Prof. Christian Mawrin, Institute for Neuropathology, University Hospital Magdeburg


Letzte Änderung: 28.04.2023 - Ansprechpartner:

Sie können eine Nachricht versenden an: Webmaster